The Effect of Botulinum Toxin A in Post Spinal Cord Injury Neuropathic Pain

Catholic University of Korea Saint Paul's Hospital1 site in 1 country40 target enrollmentApril 2012

ConditionsSpinal Cord Injury Neuropathic Pain

InterventionsBotulinum toxin type A normal saline

DrugsBotulinum toxin type A normal saline

Overview

Phase: Phase 4
Intervention: Botulinum toxin type A
Conditions: Spinal Cord Injury
Sponsor: Catholic University of Korea Saint Paul's Hospital
Enrollment: 40
Locations: 1
Primary Endpoint: Visual analogue scale
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to determine whether botulinum toxin A is effective in the treatment of neuropathic pain in spinal cord injury patients.

Detailed Description

Neuropathic pain remains a significant cause of life quality deterioration. This study includes spinal cord injury patients with refractory chronic neuropathic pain and investigates whether injection with botulinum toxin A improves pain scores.

Registry

clinicaltrials.gov

Start Date

April 2012

End Date

April 2013

Last Updated

13 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Catholic University of Korea Saint Paul's Hospital

Responsible Party

Principal Investigator

Myung Eun, Chung

clinical assistant proffessor

Catholic University of Korea Saint Paul's Hospital

Eligibility Criteria

Inclusion Criteria

•more than twenty years of age
•paraplegic or tetraplegic due to cervical and thoracic spinal cord injury
•more than 12 months since spinal cord injury and ASIA impairment scale unchanged for more than 6 months
•persistence of neuropathic pain for more than three months or remission and recurrence of neuropathic pain for more than six months
•a pain score of 40mm or more on the visual analogue scale

Exclusion Criteria

•neuropathic pain caused by confounding factors other than spinal cord injury
•contraindicated for botulinum toxin type A
•a change in pain medication one month prior to study enrollment
•a condition involving neuromuscular junction (Ex. Eaton Lambert disease, myasthenia gravis)
•person who received botulinum toxin type A within three months prior to study enrollment